MINNEAPOLIS–(BUSINESS WIRE)–Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the appointment of Paul Friel to its Board of Directors. The appointment comes as Vergent prepares for a potential New Drug Application (NDA) filing and commercialization of abenacianine in lung cancer surgery, while continuing to advance the technology across additional oncology indications. Mr. Friel brings more than 30 years of commer